Merck To Pay Up To $425m For Foghorn’s Gene Regulation Therapies

Major Deal For ‘Gene Traffic Control’ Company

 
• By Andrew McConaghie
Cambridge
The Cambridge, MA-based firm has been around since 2016, and came out of 'stealth mode' two years ago

More from Business

More from Scrip